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Background: Evidence for non-steroidal anti-inflammatory drugs (NSAIDs) preventing head and neck cancer (HNC) is
inconclusive; however, there is some suggestion that aspirin may exert a protective effect.
Methods: Using data from the United States National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial, we examined the association between aspirin and ibuprofen use and HNC.
Results: Regular aspirin use was associated with a significant 22% reduction in HNC risk. No association was observed with regular
ibuprofen use.
Conclusion: Aspirin may have potential as a chemopreventive agent for HNC, but further investigation is warranted.
Over 600 000 cases of head and neck cancer (HNC) occur annually
(Freedman et al, 2007). Primary risk factors include tobacco use
and excessive alcohol consumption (WHO, 2009). Head and neck
cancer is associated with high levels of morbidity and mortality
(Jayaprakask et al, 2006).
Several studies have shown non-steroidal anti-inflammatory
drugs (NSAIDs) to reduce cancer risk (Rothwell et al, 2010, Bosetti
et al, 2012). A systematic review by our group investigated the
association between NSAID use and HNC (Wilson et al, 2011).
Five studies met the inclusion criteria but each had significant
limitations, including small sample size, lack of information on
over-the-counter NSAID use and important confounding factors
(Bosetti et al, 2003; Friis et al, 2003, 2006). Two studies indicated a
protective effect of aspirin on HNC risk (Bosetti et al, 2003;
Jayaprakash et al, 2006).
An upregulation of the expression of the inducible, inflamma-
tory cyclo-oxygenase enzyme (COX-2) has been observed in many
cancers, including HNC, and premalignant head and neck lesions
(Mohan and Epstein, 2003; Altorki et al, 2004). It is thought
NSAIDs may prevent cancer development by inhibiting COX-2
and the downstream biological pathways implicated in carcinogen-
esis (Liao et al, 2007); other COX-2 independent pathways have
also been suggested (Hwang et al, 2002: Kashfi, Ragas, 2005).
Using data from the National Cancer Institute Prostate, Lung,
Colorectal and Ovarian Cancer (PLCO) randomised controlled
screening trial a large scale prospective investigation of the effect of
aspirin and ibuprofen on HNC risk was undertaken.
MATERIALS AND METHODS
The PLCO trial design is described in detail elsewhere (Prorok
et al, 2000). Between November 1993 and September 2001, almost
155 000 participants aged 55–74 years were recruited from ten US
screening centres and randomly assigned to an intervention arm
(screened for colorectal, lung, and ovarian or prostate cancer) or
usual care arm. Over 99% of participants were followed up
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annually for cancer diagnosis and death. Cancer confirmation was
ascertained from diagnostic information.
This investigation includes cases from both arms of the
PLCO trial with no previous cancer history who completed the
baseline questionnaire and provided information on aspirin and
ibuprofen use. Participants were followed from enrolment to
31 December 2006.
Cases were defined as individuals diagnosed with a primary
HNC at least 1 year after completion of the baseline questionnaire.
Head and neck cancer sites comprised International Classification
of Disease for Oncology version-2 topography codes C00.0-C14.8
and C30.0–C32.9. Lip cancers were excluded as the primary
aetiology (exposure to UV light) was considered dissimilar to that
of other included cancer sites.
Information on demographic characteristics, medical history,
aspirin or ibuprofen use, anthropometric measures, and lifestyle
was collected at baseline using a comprehensive self-completed
questionnaire. Aspirin and ibuprofen use elicited a yes/no response
to the following questions: during the last 12 months have you
regularly used ‘aspirin or aspirin-containing products such as
Bayer, Bufferin, or Anacin’, or ‘ibuprofen containing products such
as Advil, Nuprin or Motrin’. Regular use was not defined.
Self-reported frequency of use was measured by the number of
tablets usually taken: 1 per day, X2 per day; 1 per week, 2 per
week, 3–4 per week;o2 per month, 2–3 per month, this was
further categorised into daily and weekly/monthly use. Further
information on frequency of use and dose usually taken (aspirin
use only), was available in a supplementary questionnaire (SQX)
completed between 2006 and 2007. Current body mass index
(BMI) was calculated and categorised according to the World
Health Organisation classification. Current smoking status was
defined as never or ever use. Maximum cigarette pack years were
calculated and categorised into quartiles. Self-reported alcohol
consumption in the 12 months preceding interview was obtained at
baseline for individuals in the screening arm.
Analysis. Using Cox proportional hazard modelling unadjusted
and multi-variable adjusted hazard ratios (AHR) and 95%
confidence intervals (CI) for HNC risk were estimated. Participants
were censored at the earliest of HNC diagnosis, death or
31 December 2006. Biologically plausible confounding variables
were initially included in the model and excluded if P-values
were 40.10. The possibility of aspirin users also using ibuprofen,
and vice versa, was included as a possible confounder in the
respective models. Body mass index values o12 and 460 kgm 2
were excluded from the model as possible outliers using listwise
deletion.
A subanalysis using participants with information on alcohol
use was conducted. Adjusted hazard ratios were calculated with,
and without, alcohol as a covariate to establish if alcohol use
altered the risk estimate. Tests for interactions between aspirin/
ibuprofen use and smoking status and alcohol use were conducted.
The effect of aspirin use on HNC risk was assessed by increasing
alcohol use within those individuals in the screening arm who
had information on alcohol use. Using available histological
data a restricted analysis was conducted using only squamous
cell carcinoma (SCC) HNCs.
Statistical analyses were conducted using STATA, version
11 (StataCorp, College Station, TX, USA). Tests of statistical
significance were two-sided. P-values o0.05 were considered
statistically significant.
RESULTS
After initial exclusions, 142 034 individuals remained eligible for
analysis. The mean follow-up time was B9 years (range 0–13.1
years), with a total person years of follow-up of 1 276 115 years.
During follow-up, 316 individuals had a confirmed HNC. Cohort
characteristics are shown in Table 1.
At baseline, 49.2% and 29.6% of participants reported regular
aspirin and ibuprofen use, respectively. The later SQX provided an
indication of aspirin strength; most non-HNC cases reporting daily
usage in both questionnaires were taking low dose (81mg) aspirin.
Those reporting weekly/monthly use in the SQX tended to take
higher doses (325mg). A shift to increased frequency of use, parti-
cularly by those reporting weekly/monthly uses was also observed.
Table 1. Baseline Characteristics of participants within Study cohort (lip
excluded)
Characteristicsa
Total cohort
(n¼142034)
HNC patients
no. (n¼316) P-value
Gender, n (%)
Male 71 643 (50.4) 244 (77.2) o0.001
Female 70 391 (49.6) 72 (22.8)
Age (years) 62.6 (5.3) 63.8 (5.0) o0.001
Family history of HNC, n (%)
Yes 1738 (1.2) 8 (2.5) 0.034
No 140 296 (98.8) 308 (97.5)
Race, n (%)
White non-hispanic 125 532 (88.4) 279 (88.3) 0.739
Black non-hispanic 7286 (5.1) 14 (4.4)
Hispanic 2684 (1.9) 9 (2.9)
Asian 5345 (3.8) 11 (3.5)
Other 1152 (0.8) 3 (0.9)
Education, n (%)
11 Years school 10 425 (7.4) 39 (12.4)
12 Years/completed high
school
32 551 (23.0) 65 (20.6) 0.005
Post school/ some
college
48 715 (34.4) 111 (35.2)
College/postgraduate 50 048 (35.2) 100 (31.8)
BMI (kgm2)b, n (%)
o18.4 1138 (0.8) 5.1665 (1.6) o0.004
X18.4 to o25 45 584 (32.6) 121 (39.0)
X25 to o30 59 457 (42.5) 132 (42.6)
X30 33 665 (24.1) 52 (16.8)
Smoking Status, n (%)
Never 65 548 (46.2) 61 (19.3) o0.001
Ever 76 450 (53.8) 255 (80.7)
Cigarette pack years max, n (%)
None 65 548 (46.9) 61 (19.8)
40–29 37 402 (26.7) 64 (20.8) o0.001
429–49 18 533 (13.3) 63 (20.4)
449 pack years 18 394 (13.1) 120 (39.0)
Alcohol usec, n (%)
Never 10 734 (17.9) 24 (18.6) 0.825
Ever 49 367 (82.1) 105 (81.4)
Abbreviations: BMI¼body mass index; HNC¼ head and neck cancer.
aContinuous variables reported as mean±s.d.
bDo not add up to 142 034 due to exclusions of outliers (124BMI 460 kgm 2).
Only excluded in adjusted COX-analysis.
cIndividuals with a dietary questionnaire only (n¼ 60,101).
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Unadjusted and multi-variable adjusted HRs for aspirin and
ibuprofen use and HNC risk are shown in Table 2. After adjusting
for possible confounders, a decreased risk of HNC was observed
with regular aspirin use (AHR 0.78, 95% CI 0.62–0.98). A
significant reduction of HNC risk was observed between weekly
and monthly aspirin use; daily aspirin use was not significantly
associated with a reduced HNC risk, Table 2. No association was
observed between ibuprofen use and HNC. When analyses were
restricted SCC sites estimates for regular aspirin and ibuprofen use
were similar to all HNCs (AHR 0.72, 95% CI 0.56–0.93; AHR 0.96,
95% CI 0.71–1.29, respectively).
The subtype specific analyses showed a significant protective
association between aspirin use and laryngeal cancer (AHR 0.67,
95% CI 0.45–0.99). An inverse, but non-significant, association
between aspirin use and cancers of the oropharynx, and ‘other sites
combined’ was observed (Supplementary Data, Table 1).
Including alcohol use as a possible confounder, the AHRs did
not alter for aspirin or ibuprofen use. A significant interaction
(P¼ 0.004) between alcohol and aspirin was observed. Stratifica-
tion by increasing alcohol use revealed an increasing reduction in
HNC risk in aspirin users compared with non-users. No protective
association was observed in non-alcohol users (Table 3).
No interaction between aspirin/ibuprofen use and tobacco use
was evident.
DISCUSSION
Consistent with other studies (Bosetti et al, 2003; Jayaprakash et al,
2006; Ahmadi et al, 2010), we report a significant reduction in
HNC risk with aspirin use, with the strongest protective effect for
laryngeal cancers. No association was observed between HNC and
ibuprofen use.
No association with ibuprofen use was observed. Compared
with aspirin use, ibuprofen use was more infrequent and taken by
proportionately fewer individuals; the reduction in power may,
therefore, explain the lack of association. In addition, our analysis
revealed a slight, non-significant, reduction in HNC risk with
increased frequency of ibuprofen use, suggesting a possible causal
effect. Alternatively, aspirin may exert different COX-2 indepen-
dent effects on reducing cancer compared with ibuprofen (Elwood
et al, 2009). A greater reduction in HNC risk was observed with
weekly/monthly aspirin use than daily use. The later SQX indicated
an increase in dosage and frequency of use among weekly/monthly
aspirin users, which may explain the absence of a protective trend
with increased frequency of use.
There was a near negligible difference between risk estimates
with alcohol included in the model. Cohort alcohol intake was
relatively low, possibly explaining the lack of effect on the HRs.
Interaction analyses suggested that alcohol may be modifying the
effect of aspirin use on HNC risk. A subanalysis in individuals
with information on alcohol use revealed an increasing reduction
in HNC risk, albeit non-significant, with aspirin use among
Table 2. Risk of head and neck cancer in relation to aspirin and non-aspirin NSAID use
HNC patients
no. n (%)a
Cohort
no. (n) (%)
Unadjusted
HR (95% CI)
Multivariate adjusted
HRb (95% CI)
Regular aspirin usec
No 165 (52.2) 71 989 (50.8) Reference Reference
Yes 151 (47.8) 69 729 (49.2) 0.96 (0.77–1.19) 0.78 (0.62–0.98)
Frequency of aspirin use
None 165 (52.4) 71 989 (50.8) Reference Reference
Monthly/weekly use 61 (19.4) 32 541 (23.0) 0.81 (0.60–1.08) 0.69 (0.51–0.93)
Daily use 89 (28.2) 37 020 (26.2) 1.08 (0.84–1.40) 0.85 (0.65–1.11) Ptrend¼ 0.141
Regular ibuprofen usec
No 234 (74.0) 99 772 (70.4) Reference Reference
Yes 82 (26.0) 41 946 (29.6) 0.86 (0.67–1.10) 0.97 (0.75–1.27)
Frequency of ibuprofen use
None 234 (74.3) 99 772 (70.5) Reference Reference
Monthly/weekly use 57 (18.1) 27 969 (19.8) 0.90 (0.67–1.20) 1.03 (0.76–1.39)
Daily use 24 (7.6) 13 680 (9.7) 0.77 (0.51–1.17) 0.86 (0.56–1.32) Ptrend¼ 0.622
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; HNC¼ head and neck cancer; NSAID¼ non-steroidal anti-inflammatory drug.
aInconsistencies in the counts of regular and frequency of both aspirin and ibuprofen use were a result of non-completion of the question relating to frequency of use.
bMultivariate adjustments: age at baseline (years), gender, BMI (o18.5, 18.5–o25, 25–o30,X30 kgm 2), tobacco use (None,40–29,429–49,449 maximum cigarette pack years); Ibuprofen
model further adjusted for aspirin use.
cRegular use was not defined.
Bold text indicates statistically significant result.
Table 3. Risk of head and neck cancer in relation to aspirin use: stratified
analysis by increasing alcohol use
Number of
alcoholic
beverages per
day
HNC
patients
no. (n) (%)
Cohort no.
(n) (%)
Multivariate
adjusted HRa
(95% CI)
Non-drinker 24 (18.7) 10 618 (17.8) 1.52 (0.65–3.51)
40–2 Drinks per day 81 (63.3) 41 493 (69.8) 0.67 (0.43–1.04)
42 Drinks per day 23 (18.0) 7317 (12.4) 0.42 (0.17–1.00)
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; HNC¼ head and neck cancer.
aMultivariate adjustments: age at baseline (years), gender, BMI (o18.5, 18.5–o25, 25–o30,
X30 kgm 2), tobacco use (none, 40–29, 429–49, 449 maximum cigarette pack years);
Reference group: non-aspirin use.
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participants with increasing alcohol use. The exact mechanism by
which this may be occurring is uncertain. Ethanol found in alcohol
has been reported to act as a local irritant (Llewellyn et al, 2001)
potentially leading to localised inflammation, which may possibly
explain the observed reduction in HNC in aspirin users who
consume alcohol. Previous studies have not reported alcohol as a
possible effect modifier, further investigation is merited.
The site-specific analysis observed a significant protective effect
with aspirin use and laryngeal cancer. The AHR was reduced for
cancers of the oropharynx; however, the association was not
significant (AHR 0.70 95% CI 0.41–1.19), possibly due to the small
numbers involved. Jayaprakash et al (2006) observed a similar
reduction in oropharyngeal cancer risk with aspirin use. The
majority of oropharyngeal sites have been described as human
papillomavirus (HPV)-related (Ramqvist and Dalianis, 2010).
There is some evidence to suggest an upregulation of COX-2 in
HPV-infected tissues (Subbaramiah and Dannenberg, 2007).
Strengths of this study include the ability to control for
important confounders, specifically tobacco use. Follow-up time
was fairly long; follow-up exceeded 99%. The study was limited by
the lack of complete information on alcohol use, with information
only available in the screening arm. However, there was little
difference between participant characteristics within the two study
arms and adjustment for alcohol had no effect on the point
estimates. Dosage was from a later questionnaire and could only
provide an indication of possible dosage.
This study supports the view that aspirin may have potential as
a chemopreventive agent for HNC. There was little evidence to
suggest that ibuprofen use was associated with reduced HNC risk.
Further studies are required, in particular, those examining the
strength and duration of aspirin use that may be required to exert a
protective effect.
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